Phase 1 N=19 Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate in Patients With Stable Severe Renal Disease.
Renal Insufficiency, Chronic
Primary: Cmax,ss — 207 ng/mL — p=0.5186
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,241 A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005)
Human Papillomavirus Infection
Primary: Geometric Mean Titers (GMTs) of the Antibody Response to Each of the Human Papillomavirus (HPV) Types Contained in V503 — 2198.7; 2260.7; 1495.0; 1547.2 milli Merck…
Phase 1 N=7 Exposure Therapy for Veterans With PTSD and Panic Attacks (Phase 1)
PTSD · Panic Attacks
Primary: Clinician Administered PTSD Scale (CAPS) — 29.5 units on a scale
N/A N=279 Supplementing Hearing Aids With Computerized Auditory Training
Hearing Loss
Primary: Words-in-Noise Test (WIN) Change — 9.8; 9.9; 9.7; 10.4 dB SNR
Phase 2 N=13 Creatine Treatment for Female Adolescents With Depression Who Are Non-Responders to Fluoxetine or Escitalopram
Major Depressive Disorder
Primary: Mean Children's Depression Rating Scale (CDRS-R) [Reference: Poznanski EO et al. Preliminary Studies of the Reliability and Validity of the Children's Depression Rating…
N/A N=178 Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA)
Rheumatoid Arthritis · Psoriatic Arthritis · Periodontal Disease
Primary: Alteration of Microbiota, Alteration of T Cell Function/Activation — 4; 10; 2; 0 participants
N/A N=100 Efficacy of a Commercial Dentifrice Containing Ilex Rotunda Thunb Extract for Dental Plaque and Gingivitis
Gingivitis · Dental Plaque
Primary: Plaque Assessment After 6 Weeks of Dentifrice Use — 2.98; 3.04 units on a scale
Phase 3 N=205 Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
Childhood Acute Basophilic Leukemia · Childhood Acute Eosinophilic Leukemia · Childhood Acute Erythroleukemia (M6)
Primary: Event-free Survival (EFS) at 3 Years — 90.1 percentage
N/A N=10 Endothelin Blockade in Patients With Single Ventricle Physiology
Congenital Heart Disease
Primary: Pulmonary Blood Flow as Determined by MRI Velocity Encoding at 3-6 Months — 3.3; 4.4 L/min — p=0.03
Phase 2 N=46 Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen
Leukemia · Hodgkin Lymphoma · Non-Hodgkin Lymphoma
Primary: Regimen Related Toxicities — 56; 70; 4; 10 toxicities
Phase 3 N=427 Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.
Parkinson's Disease
Primary: Efficacy of 2 BIA 9-1067 (25 mg, and 50 mg) Compared With Placebo, When Administered With the Existing Treatment of L-DOPA Plus a DDCI (DOPA Decarboxylase Inhibitor)…
Phase 3 N=1,070 Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia
Leukemia
Primary: Event-free Survival at 3 Years — 46.9; 53.1; 50.0 percentage of participants
Phase 1 N=30 Effect of Repeated Administration of Eslicarbazepine Acetate on the Pharmacokinetics of Simvastatin in Healthy Subjects
Epilepsy
Primary: Simvastatin Cmax (Maximum Plasma Concentration) — 17.7; 6.89 ng/mL
Phase 3 N=805 Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1
Meningococcal Disease · Meningococcal Meningitis
Primary: Percentages of Subjects With Persisting Serum Bactericidal Titers ≥1:5 and ≥1:8 (at 4 Years of Age), Who Had Previously Received Three Primary Doses and One Booster Dose…
N/A N=269 Complete Histologic Resection of Adenomatous Polyps?
Adenomatous Polyps
Primary: Percent of Incompletely Resected Adenomatous Polyps — 10.1 percentage of incomplete resection